FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

Educational attainment is linked to reduced white matter hyperintensity burden in older adults, with vascular risk factors serving as a key mediator.

A mobile phone application can characterize patterns of recovery from neurological manifestations of post-acute sequelae of severe acute respiratory syndrome co ...

Circadian misalignment in adolescents is linked to structural changes in brain regions that regulate emotional processing and cognitive function.

An elevated neutrophil-to-lymphocyte ratio is associated with a significantly higher prevalence of depressive disorder.

Americans are signing up for Obamacare this year after extra financial help that lowered monthly premiums expired.

The Food and Drug Administration (FDA) has approved Zycubo® (copper histidinate) for the treatment of Menkes disease in pediatric patients.

The CASTLE Online Sleep Intervention may help reduce sleep onset latency for children with epilepsy when paired with standard ...

Epigenetic age acceleration appears to be associated with worse neurocognitive function for those that survive childhood ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

Interdisciplinary multimodal pain treatments yield small but clinically relevant improvements in pain and physical functioning for patients with chronic pain.

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2025. The list includes several groundbreaking therapies that are expected to change the ...